Tango Therapeutics Inc (TNGX) - News Archive

Tango Therapeutics: Advancing Precision Cancer Medicines with Promising Clinical Data and Strategic Growth Tango Therapeutics, Inc. (NASDAQ: TNGX), a distinguished player in the realm of biotechnology, stands at the for...

In a recent announcement, Tango Therapeutics, a clinical-stage biotechnology company focused on advancing precision cancer medicines, revealed the discontinuation of its TNG348 program. The decision came as a result of...

Tango Therapeutics, a prominent clinical-stage biotechnology company, recently made an exciting announcement regarding its upcoming participation in several investor conferences. The company prides itself on its dedicat...

In a bid to revolutionize the field of precision cancer medicines, Tango Therapeutics, a clinical-stage biotechnology company, recently announced the granting of non-qualified stock options and restricted stock units (R...

Tango Therapeutics Initiates Phase 1/2 Trial of TNG348 in BRCA1/2-Mutant and HRD+ CancersTango Therapeutics, a renowned clinical-stage biotechnology company specializing in precision cancer medicines, recently announced...